九源基因：创新药JY54注射液临床试验申请获受理

Core Viewpoint - Jiuyuan Gene's self-developed innovative drug JY54 injection has received formal acceptance for clinical trial application by the National Medical Products Administration, marking a significant step in the company's focus on metabolic disease treatment [1][2] Group 1: Product Development - JY54 injection is a long-acting glucagon-like peptide-1 (GLP-1) analog aimed at weight management for overweight or obese individuals, with the first phase of clinical research planned to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics [1] - The drug's molecular design has undergone systematic optimization to enhance drug stability and pharmacokinetic characteristics, potentially supporting long-acting administration [1] Group 2: Strategic Positioning - Jiuyuan Gene is expanding into high-tech metabolic treatment areas, reflecting its ongoing investment in innovative drug development [1] - The company has established a clear gradient layout in its product pipeline, combining mature target products with innovative mechanisms to meet current market demands and explore future weight loss treatment directions [2]